Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Infectious Diseases

Topics

Medicine

Pathology

Internal Medicine

Surgery

Neurology

Show all topics

DOI

10.1016/s1473-3099(24)00431-6

License

CC-BY